Opens in a new tab or window HOUSTON -- An early molecular or cytogenetic response correlated with better long-term survival in heavily pretreated chronic-phase chronic myeloid leukemia (CML ...

The aim of the present study was to clarify the relation between early ... to molecular response at 3 months The approval of second-generation TKIs for frontline treatment of CML gave rise to ...

Early molecular response (EMR, BCR-ABL1 (IS)⩽10% at 3 months) is a strong predictor of outcome in imatinib-treated chronic phase chronic myeloid leukemia (CP-CML) patients, but for patients who ...

Reaching a major molecular response shows doctors that your treatment is lowering the number of cancerous cells in your body. An older 2011 study found that people with CML who achieved an early ...

Here, we investigated whether early molecular response before 3 mo was associated with subsequent cytogenetic response. Methods: CML-CP pts (N = 321) with imatinib resistance or intolerance were ...

We assessed the efficacy and safety of dasatinib, as compared with imatinib, for the first-line treatment of chronic-phase CML ... including major molecular response, were tested at a significance ...

in CML to define prognostic markers to increase the rate of patients in durable deep molecular response after stopping TKI. On the second day of the 56th Annual Meeting of the American Society of ...

Opens in a new tab or window A new study of patients with chronic myeloid leukemia (CML ... can best predict the achievement of a deep molecular response that lasts at least 2 years.

Novartis is hoping that Scemblix (asciminib) will become the physician’s first choice of therapy for chronic myeloid ...

In a second poster, researchers from Greece analyzed front-line TKI selection in CML. They investigated the role of early molecular response (EMR) in the long-term outcome based on the first-line TKI.

15, 2005 (Atlanta) ― Patients with chronic myeloid leukemia ... depth of the response initially predicts relapse outcome." Dr. Radich said if a deep response can be obtained early on in a ...

Nilotinib versus imatinib in patients (pts) with newly diagnosed chronic myeloid leukemia in chronic phase (CML-CP): ENESTnd 3-year (yr) follow-up (f/u). This is an ASCO Meeting Abstract from the 2012 ...